Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 23
- 主要终点
- Typical daptomycin clearance
研究概览
简要总结
Daptomycin is a cyclic lipopeptide that has been proposed as an alternative therapeutic option in patients with prosthetic joint infection caused by Staphylococcus or Enterococcus species in the latest Infectious Diseases Society of America (IDSA) guidelines.
The population pharmacokinetics (PK) of daptomycin have been described in various groups of patients in previous publications. However, little information exists on the PK of daptomycin in patients with bone and joint infections (BJI). Also, previous population studies did not investigate daptomycin PK over prolonged therapy, and, to our knowledge, no study has reported the intraindividual PK variability of this drug.
The aim of this study is to describe the inter- and intraindividual PK variability of this drug.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients treated with daptomycin for BJI in Lyon Center in 2012 and 2013
排除标准
- 未提供
结局指标
主要结局
Typical daptomycin clearance
时间窗: 6 months
Mean daptomycin plasma clearance (unit, liters per hour) Outcome measures performed regularly in those patients throughout therapy, roughly every month.
Typical daptomycin volume of distribution
时间窗: 6 months
Mean daptomycin volume of distribution (unit, liters) in the population
次要结局
未报告次要终点